PT  - JOURNAL ARTICLE
AU  - Niino, Mariko
AU  - Tomizuka, Taro
AU  - Nishina, Yuka
AU  - Ichinose, Yuichi
AU  - Gonoi, Wataru
AU  - Higashi, Takahiro
TI  - A survey on the nationwide prevalence of asbestos-related lung cancer in Japan
AID  - 10.1101/2024.10.27.24316218
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.27.24316218
4099  - http://medrxiv.org/content/early/2024/10/29/2024.10.27.24316218.short
4100  - http://medrxiv.org/content/early/2024/10/29/2024.10.27.24316218.full
AB  - BACKGROUND An accurate estimate of the nationwide prevalence of asbestos-related lung cancer (ARLC) is necessary to adequately operate a compensation subsidy program for patients with ARLC. Our study aimed to estimate the proportion of patients with ARLC among patients with primary lung cancer, and describe the characteristics and distribution of ARLC.METHODS All facilities that treated patients diagnosed with lung cancer in 2016 were requested to submit computed tomography images of 10 patients randomly selected from the national databases of hospital-based cancer registries. ARLC was defined as pleural plaques (PPs) extending over one-quarter of the inner lateral chest wall or existing PPs accompanied by obvious lung fibrosis. We estimated the proportion and distribution of ARLC among primary lung cancer cases and compared the characteristics of ARLC with those of primary lung cancer.RESULTS Of 772 facilities that treated at least one patient with lung cancer, 370 provided 3,565 sets of CT images. Of these, 216 (6.1%) had PPs, and 86 (2.4%) met the compensation criteria. After sample weighting, 2.0% of all primary lung cancers were classified as ARLC in Japan. A higher percentage of patients with ARLC were male (94.2% vs. 68.6%; P < .01) and had more advanced-stage disease (stage III: 22.1% vs. 16.0%; stage IV: 44.2% vs. 39.8%; P =.05) than other primary lung cancers. A majority (53.5%) of patients with ARLC were diagnosed at designated cancer hospitals. The proportion of squamous cell carcinoma was higher in ARLC than in those with primary lung cancer (25.6% vs. 18.6%; P < .01).CONCLUSION The estimated number of patients with ARLC was larger than expected from the number of applicants in the compensation system for asbestos-related health damages (AHDRS). Consequently, countermeasures are required to accurately identify eligible compensation recipients.HighlightThe estimated proportion of patients with ARLC among patients with lung cancer was 2%.The proportion of squamous cell carcinoma was higher in ARLC than in primary lung cancer.A higher number of ARLC cases than expected from the official reports of AHDRS compensation recipients in Japan was found. More accurate AHDR reports are neededCompeting Interest StatementThe authors have declared no competing interest.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the Institutional Review Board of the National Cancer Center, JapanI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableAlthough the data used in this study are anonymized when obtained from facilities, we have not obtained consent from the participants to share the data with third parties or to make the data public. Therefore, the use of the data is restricted.ARLCasbestos-related lung cancerAHDRSAsbestos Health Damage Relief SystemCTcomputed tomographyAHDASAsbestos Health Damage Assessment SubcommitteeHRCRHospital-Based Cancer RegistryPPspleural plaques